The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market.

The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market. On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.  

COVID-19 Impact on Global RNA Analysis Market 

According to our findings, the RNA analysis/transcriptomics market is expected to grow at an approximate CAGR of 15–17% for the next two years. The factors listed below would play a key role in shaping the growth of the global market; 

With the increased need for faster testing and research, the demand for transcriptomic technologies has also increased, especially in the areas of NGS and PCR. The FDA has approved various oncology profiling tests, such as PCR testing panels and drugs, for emergency use in COVID-19 testing and diagnostics.
Transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients is being undertaken to characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection. This is being utilized for clinical guidance on anti-inflammatory medication and understanding the molecular mechanisms of host response to come up with effective therapeutics.
The outbreak of COVID-19 has been increasing at an exponential level in the US. This has led to a decline in regular patient visits to hospitals and clinics and the number of profiling studies being conducted under normal circumstances. This is expected to inhibit market growth to a certain extent.  


With the widespread implementation of novel applications, the use of transcriptomics research extends all the way from the discovery of novel drugs, vaccines, and diagnostic targets, toxicology, and identification of surrogate markers of activity in clinical research to the ability to provide information on the mechanisms of drug action. This requires the use of different types of platforms and instruments as well as laboratory documentation systems, contributing to the high cost of analytics. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576

The sequencing technologies segment is expected to witness the highest growth during the forecast period. RNA sequencing allows direct access to sequences of mRNA and is an equitable technology, which makes it more suitable for target identification and drug discovery applications. RNA sequencing also helps overcome several issues associated with microarrays, such as bias and variation due to hybridization and labeling efficiencies. Technological advancements in this segment are further set to drive market growth.  

This is attributed to the use of transcriptomics in drug discovery for target identification and validation, identification of efficacy and toxicity biomarkers from biological fluids, and investigation of drug action and toxicity mechanisms. The growing need to study a large number of genes to gain a better understanding of gene-to-drug interactions is further expected to drive the use of transcriptomic technologies in drug discovery applications.  

Key Market Players

The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US).